Onset: Slow — days to weeks. Cortexin is not an acute-effect peptide. Most users describe nothing distinct in the first 3-5 days of an IM course.

Peak / character (per Russian patient and Western self-experimenter reports):

• Mild improvement in cognitive symptoms (concentration, mental clarity) emerging during week 2 of a 10-day course
• Modest mood lift in some users; not euphoric or activated
• Some reports of improved sleep quality
• Generally described as "milder than Cerebrolysin" subjectively

Characteristic absences:

• No stimulant effect, no acute "feel" within an hour of dose
• No appetite change
• No crash on cessation

Honest variability:

• A meaningful fraction of self-experimenters report no detectable subjective effect (consistent with the mechanism being downstream / protective rather than acute, and consistent with possibly sub-therapeutic dosing in some Western community protocols).
• For Dylan's archetype (already-optimized 20yo): expect modest-to-subtle subjective effect at best, similar profile to Cerebrolysin but likely weaker. This isn't a strike against the compound — it's the expected character of a slow neurotrophic intervention — but it makes attribution difficult and reinforces the question "why not just use Cerebrolysin?"

• Tolerance buildup: Unknown / not characterized. The cycled Russian protocol (10-20 days on, 3-6 months off) implies developers assumed some kind of cycling necessity, but no tolerance studies are published.
• Recommended cycle: 10-20 days IM, every 3-6 months. Do not exceed 20 consecutive days.
• Reset protocol: 3-6 month off-cycle is the reset.
• No physical dependence, no withdrawal syndrome documented.

Synergistic with (theoretical)

• cerebrolysin — Mechanistically redundant. Cortexin and Cerebrolysin are both animal-cortex peptide hydrolysates with the same neurotrophic-cocktail claim. Running both is the wrong move — if Cerebrolysin is the higher-evidence pick (it is), Cortexin adds redundancy without differentiating benefit. If you wanted to test Cortexin specifically, you would do a Cortexin course in a Cerebrolysin off-cycle, not co-administer.
• semax / n-acetyl-semax-amidate — Mechanistically complementary (Semax acts on melanocortin / BDNF / neurotrophic axes; Cortexin's broad peptide-cocktail mechanism is too poorly characterized to predict specific synergy). No documented interaction; safe to co-administer.
• dylan's V4 antioxidant base (NAC, curcumin, astaxanthin, vitamin C) — likely additive if anything, no interaction concern.

Avoid stacking with

• Cerebrolysin simultaneously — redundancy without benefit. Run them in separate cycles if running both.
• Other Khavinson-network peptide bioregulators simultaneously (Pinealon, Cerluten, Vesugen) — running multiple Khavinson-network products at once makes attribution impossible and stacks the same single-source-evidence problem.

Neutral / safe co-administration

• Dylan's V4 base stack (citicoline, Mg L-threonate, NAC, fish oil, PS, rhodiola, theanine, B-complex)
• Creatine
• Modafinil, caffeine, Bromantane, Adamax, Selank — no documented interactions.

• No documented CYP induction/inhibition. Peptide complex metabolized by peptidases, not CYP enzymes.
• No documented interactions with hormonal contraceptives, statins, antidepressants, or other CYP-substrate medications.
• Theoretical: GABA-ergic / sedative additive. Some claimed GABA-modulatory activity. If real, mild additive sedation possible with benzodiazepines, gabapentin, or other GABA-active drugs. Practical impact likely minimal.
• No documented interactions with other Russian peptides Dylan would stack (Semax, Adamax, Cerebrolysin, Selank, Bromantane).

• None established. No published polymorphism-stratified data for Cortexin response.
• Speculative, untested: APOE genotype, BDNF Val66Met, MTHFR variants — none specifically linked to Cortexin in published work.

Cold chain considerations

• Lyophilized vial: Stable at room temperature (per manufacturer label, typically <25°C, dry, dark) prior to reconstitution. Many Russian peptide products tolerate ambient shipping for several weeks.
• After reconstitution: Use within hours; refrigerate if delayed.

Sourcing strategy for Dylan

N/A — verdict is SKIP-FOR-NOW. If verdict ever changed, the path would be CosmicNootropic or RUPharma 10×10mg adult-strength vials, ~$60-90 for a full 10-day course.

If Cortexin were ever used (it isn't, per verdict):

• Baseline: subjective cognitive VAS, CNS Vital Signs / Cambridge Brain Sciences cognitive battery, sleep quality (Oura/Whoop). Optional: serum BDNF, NfL, GFAP, S100B (athletes), hsCRP.
• During use: daily VAS, weekly cognitive battery, weekly sleep, injection site monitoring.
• Post-cycle: repeat cognitive battery + biomarkers 7-14 days post-cessation.

• [cerebrolysin] — the higher-evidence alternative for Cortexin's exact mechanistic role. Same animal-cortex peptide hydrolysate concept, vastly better evidence base (multi-decade international RCTs, CAPTAIN TBI series, 2023 ESO stroke guideline). PRIMARY-PICK in Dylan's V5 stack. Cortexin adds nothing differentiating.
• [epithalon] — Khavinson tetrapeptide targeting telomerase / pineal melatonin axis. Different mechanistic class (defined synthetic short peptide vs Cortexin's complex peptide hydrolysate). No mechanistic overlap with Cortexin.
• [pinealon] — Khavinson short tripeptide (Glu-Asp-Arg) with claimed epigenetic / DNA-binding mechanism. Different class than Cortexin (defined synthetic short peptide vs complex peptide hydrolysate). Pinealon's WATCH-LIST verdict reflects more concrete mechanism work (5xFAD-M dendritic spine preservation, n=72 Russian human TBI trial) than Cortexin's broader-but-thinner clinical dossier.
• [semax] — Russian heptapeptide (ACTH4-10 analog). Strong evidence base; not in Cortexin's mechanistic class but a daily-driver Russian peptide that covers BDNF / neurotrophic role partially overlapping with what Cortexin claims to do.